| Literature DB >> 36091438 |
Sara Ranjbari1, Mahdieh Darroudi2,3, Behnaz Hatamluyi4, Reza Arefinia1, Seyed Hamid Aghaee-Bakhtiari3, Majid Rezayi3,5,6, Majid Khazaei2,6.
Abstract
Breast cancer is the second most common cancer worldwide. Prognosis and timely treatment can reduce the illness or improve it. The use of nanomaterials leads to timely diagnosis and effective treatment. MXenes are a 2D material with a unique composition of attributes, containing significant electrical conductance, high optical characteristics, mechanical consistency, and excellent optical properties. Current advances and insights show that MXene is far more promising in biotechnology applications than current nanobiotechnology systems. MXenes have various applications in biotechnology and biomedicine, such as drug delivery/loading, biosensor, cancer treatment, and bioimaging programs due to their high surface area, excellent biocompatibility, and physicochemical properties. Surface modifications MXenes are not only biocompatible but also have multifunctional properties, such as aiming ligands for preferential agglomeration at the tumor sites for photothermal treatment. Studies have shown that these nanostructures, detection, and breast cancer therapy are more acceptable than present nanosystems in in vivo and in vitro. This review article aims to investigate the structure of MXene, its various synthesis methods, its application to cancer diagnosis, cytotoxicity, biodegradability, and cancer treatment by the photothermal process (in-vivo and in-vitro).Entities:
Keywords: MXene; advanced nanomaterials; biomedical analysis; biomedicine; biosensor; breast cancer; cancer treatment
Year: 2022 PMID: 36091438 PMCID: PMC9449700 DOI: 10.3389/fbioe.2022.984336
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1(A) Periodic table of the elements utilized from MAX phases (Wang et al., 2018), (B) Image of etching layers A from the corresponding MAX phases (Naguib et al., 2014).
Various types of MXenes synthesis methods.
| Types of MXenes | Methods | Application | Refs |
|---|---|---|---|
| Ti3C2Tx | Acid (HCl + LiF) | Direct absorption solar collectors |
|
| Ti3C2Tx | Acid | Heterogeneous catalysts |
|
| HF | |||
| Ti3C2Tx | Acid (HCl + LiF) | Flexible Supercapacitors |
|
| Ti3C2Tx | Acid (HCl + LiF) | Adsorption |
|
| Ti3C2Tx | Acid (HCl + LiF) | Adsorption |
|
| Ti3C2 | Acid (NH4HF2) | electrocatalyst |
|
| Ti3C2Tx | Acid | Gas barrier nanocomposite films |
|
| HF | |||
| Ti3C2 | Acid (NH4HF2) | Energy storage properties and thermal conductivity |
|
| Ti2NTx | Acid | Biological activity |
|
| HF | |||
| V2CTx | Acid | Aluminum Batteries |
|
| HF | |||
| Ti2N | Acid | Surface-Enhanced Raman Scattering Substrate |
|
| HF | |||
| Ti3C2Tx | NH3F | supercapacitors |
|
| Zr3C2Tx | Acid | Electrical energy storage |
|
| HF | |||
| Ti3C2Tx | Acid (HCl + LiF) | Electrochemical sensor |
|
| Ti3C2Tx | NaOH | — |
|
| Ti4N3 | Molten salts | — |
|
| (Mo2Ti2)C3Tx | TBAOH + HF | Thermoelectricity |
|
FIGURE 2(A) The biosensor processes principle (Kivirand et al., 2013) (B)Schematic of the electrochemical biosensor (BSA/anti-CEA/f-Ti3C2-MXene/GCE) for CEA diagnosis, (C) diagram of electrochemical biosensor replies at various concentrations of CEA (Kumar et al., 2018).
FIGURE 3(A) Schematic of competitive aptasensor manufacturing and detection method, (B) diagram of electrochemical biosensor replies at various concentrations of MUC1 (Wang et al., 2020).
FIGURE 4(A) Schematic of manufacturing electrochemical biosensor based Au/MXene to diagnosis miRNA-155, (B) diagram of electrochemical biosensor replies at various concentrations of miRNA-155 (linear range from 1.0 fM −10 nm) (Yang et al., 2020).
FIGURE 5(A) Schematic of manufacturing photoelectrochemical biosensor based a Ti3C2:CdS to detect miRNA159c (Liu S.-T. et al., 2020), (B) Schematic of manufacturing ECL biosensor based on MQD/Au to detect miRNA-26a (Nie et al., 2021).
The types of MXene-based biosensors for detecting breast cancer.
| Target | Nanoparticle | Type of biosensor | Linear range/LOD | Refs |
|---|---|---|---|---|
| miRNA-26a | MQD@Gold | Electrochemiluminescence | Linear range = 5 fM to 10 nM |
|
| LOD = 1.7 fM | ||||
| MUC1 | MXene/Au | Electrochemical aptasensor | Linear range = 1.0 pM–10 μM LOD = 0.33 p.m. |
|
| miRNA-155 | AuNPs/Ti3C2 MXene | Electrochemical biosensor | linear range = 1.0 fM to 10 nM |
|
| LOD = 0.35 fM | ||||
| CEA | Ti3C2-MXene | Electrochemical biosensor | Linear range = 0.0001–2000 ng ml−1 |
|
| LOD = 0.000018 ng ml−1 | ||||
| microRNA159c | Ti3C2:CdS | Photoelectrochemical biosensor | Linear range = 1.0* 10–6–1.0 * 10–13 mol L−l |
|
| LOD = 33 fmol L−1 |
FIGURE 6The relative viability of MCF7 cells since incubation (various concentrations) (A) Au/MXene and (B) Au/Fe3O4/MXene and Ti3C2 (MXene) following by NIR 808 nm laser radiance with a might density of 1.0 W/cm2 for 5 min Standardized to control (without laser treated cells) (Hussein et al., 2019).
FIGURE 7(A) Schematic of Ti3C2-IONPs-SPs synthesis and their multiple functions for tumor theranostics, (B) IR thermographic photographs of cancer mice afore and behind infusion of Ti3C2-IONPs-SPs nanocomposite followed by NIR radiance, (C) the temperature rise of tumors within the NIR radiance flow, (D) Digital images of mice with 4T1 tumor on the 16th day behind PTT therapies, (E) Tumor volume change plots of different groups of mice carriers of the tumor behind various therapies. (F) Collected digital images of tumors for every group at the PTT therapy end (Liu et al., 2018b).
FIGURE 8(A) Schematic representation of V2C-NSs synthesis and usages for PTT, (B) MTT method, and (C) result of Calcein AM/PI dual coloring of MCF-7 cell livability remedied with different treatment groups, (D) Tumor size photograph (Zada et al., 2020).
FIGURE 9(A) The V2C-TAT@Ex-RGD preparation process and schematic of nuclear organ and cancer cell membrane with the dual objective of V2C-TAT@Ex-RGD nano-agent for PTT. (B) Check Cell viability of different cells (MCF-7, A549, and NHDF cells) were incubated at various concentrations V2C-TAT@Ex-RGD, (C) relative tumor growth plots in multiple groups (Cao et al., 2019).
Investigated biocompatibility, photothermal conversion efficiency, and the effect of MXene nanoplate cell ablation on different types of breast cancer cells.
| Composition | Wavelength | Photothermal conversion efficiency | Cell line | Result/biocompatibility | Strategy | Refs |
|---|---|---|---|---|---|---|
| Au/MXene | NIR-I (Laser 808 nm, 1W/cm2) | — | MCF-7 |
| PTT |
|
| Au/Fe3O4/MXene | ||||||
| Ti3C2-IONPs-SPs | NIR-I (Laser 808 nm, 1.5W/cm2) | 48.6% | 4T1 | Ti3C2-IONPs-SPs have significant photothermal conversion efficiencies (48.6%) to decrease tumor tissues and kill cancer cells | PTT |
|
| For Nanocomposite (Laser-free), no displayed cytotoxicity was observed | ||||||
| V2C-TAT@Ex-RGD | NIR-II (Laser 1,064 nm, 0.96W/cm2) | 45.05% | MCF-7 | Cell viability (>90%) for The V2C-TAT@Ex-RGD in different cells (MCF-7, NHDF and A549, | PTT |
|
| The V2C-TAT@Ex-RGD + Laser group showed substantial and effective suppression of tumor growth, and no recurrence occurred ( | ||||||
| V2C-NSs | NIR-I (Laser 808 nm, 0.48 W/cm2) | 48% | MCF-7 | Low toxicity in | PTT |
|
| Nb2C-MSNs-SNO | NIR-II (Laser 1,064 nm, 1.5 W/cm2) | 39.09% | HUVEC, 4T1 | There is slight cytotoxicity to HUVEC and 4T1 cells, No chronic or acute response | PTT |
|
| Ti3C2-SPs | NIR-I (Laser 808 nm, 1W/cm2) | 74.6% | 4T1 | #0D0D0D; Ti3C2 is a drug delivery (DOX) nano-platform for effective chemotherapy with great photothermal transformation ability of Ti3C2 for tumor deracination by photothermal ablation (both | PTT/chemotherapy |
|
| Ti2C-PEG | NIR-I (Laser 808 nm) | 87.1% | MCF-7 non-malign MCF-10A | Fine bio-compatibility | PTT/Photodynamic |
|
| Nb2C-PVP | NIR-I (Laser 750–1,000 nm, 1W/cm2) and NIR-II (Laser 1,000–1,350 nm, 1W/cm2) | NIR-I = 36.4% | 4T1 | Nb2-PVP has little cytotoxicity ( | PTT |
|
| NIR-II = 45.65% | PPT ablation and tumor deracination (performance effective in both NIR-II and NIR-I, | |||||
| HAP/CS/HA/MXene | NIR-I (Laser 808 nm, 2 W/cm2) | HAP/CS/HA/MXene = 13.76% | MCF-7 | Nanoplatforms have good bio-compatibility ( | PTT/drug delivery |
|
| HAP/CS/HA/MXene/AuNRs | HAP/CS/HA/MXene/AuNRs = 20.42% | |||||
| Ti3C2-CoNWs | NIR-I (Laser 808 nm, 2 W/cm2) | 34.42% | 4T1 | Ti3C2-CoNWs nanocarriers show great photothermal transformation efficiency under Laser radiance and excellent medicine loading capacity (DOX, 225.05%) | Chemo-PTT/drug delivery |
|
| H-Ti3C2-PEG | NIR-II (Laser 1,064 nm, 1 W/cm2) | Ti3C2 = 50.8% | 4T1 | Nanoplatforms have good biocompability and stability ( | PTT and SDT |
|
| It is important to note that H-Ti3C2-PEG is eliminated from the body. Furthermore, they arenot harmful long-term |